Identification of responders to immune checkpoint therapy: which biomarkers have the highest value?
Open Access
- 13 December 2019
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (S8) , 52-56
Abstract
Evasion of immune recognition by the innate and acquired immune system is a major principle of tumour cells and belongs to the hallmarks of cancer. Immune checkpoint inhibitor‐based cancer therapies targeting the co‐inhibitory receptors CTLA‐4 or PD‐1 have received enormous scientific and clinical attention during the last few years, because of promising clinical results observed in the treatment of different cancer entities including melanoma and cutaneous squamous cell carcinoma. However, the enthusiasm about the effects of the immune checkpoint inhibitors is muted as only a subfraction of patients shows a stable clinical response. To predefine the patient cohorts that may benefit from immune checkpoint therapy, rigorous biomarker analyses, which predict the response to these novel therapies, need to be performed. In addition, combination of immune checkpoint therapy with classical DNA‐damaging chemotherapy or radiotherapy, which positively affects tumour neo‐antigen presentation, appears to be a promising approach in optimizing patients’ response. In this review, we briefly summarize important biomarkers for patient stratification and discuss the current limitations of these biomarkers in defining responders vs. non‐responders to immune checkpoint therapy.Keywords
Funding Information
- Sonderforschungsbereich (SFB 1361)
This publication has 26 references indexed in Scilit:
- Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell CarcinomaAmerican Journal of Clinical Dermatology, 2019
- A defined commensal consortium elicits CD8 T cells and anti-cancer immunityNature, 2019
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsScience Translational Medicine, 2016
- Immunological hallmarks of stromal cells in the tumour microenvironmentNature Reviews Immunology, 2015
- MelanomaNature Reviews Disease Primers, 2015
- The future of immune checkpoint therapyScience, 2015
- T cell exclusion, immune privilege, and the tumor microenvironmentScience, 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNature Immunology, 2013